SRS11-92

SRS11-92 is a ferroptosis inhibitor and a derivative of ferrostatin-1 (Item No. 17729).¹ It inhibits ferroptotic cell death induced by erastin (Item No. 17754) in HT-1080 human fibrosarcoma cells (EC₅₀ = 6 nM). SRS11-92 (2 µM) inhibits iron-induced cell death in isolated mouse kidney proximal tubules, and fully protects rat oligodendrocytes from cystine deprivation-induced cell death in an in vitro model of periventricular leukomalacia when used at a concentration of 100 nM. It also increases survival of medium spiny neurons in rat corticostriatal brain slices in an in vitro model of Huntington’s disease in a concentration-dependent manner. SRS11-92 (3 µM) increases production of reactive oxygen species (ROS) in L. major promastigotes in a time-dependent manner.² It is selectively toxic to L. major promastigotes (LD₅₀ = 3.34 µM) over U2OS human osteoblasts, RAW 264.7 macrophages, and intraperitoneal macrophages when used at a concentration of 80 µM.

WARNING This product is not for human or veterinary use.

1. Skouta, R., Dixon, S.J., Wang, J., et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136(12), 4551-4556 (2014).

2. Iniguez, E.A., Perez, A., Maldonado, R.A., et al. Novel arylalkylamine compounds exhibits potent selective antiparasitic activity against Leishmania major. Bioorg. Med. Chem. Lett. 25(22), 5315-5320 (2015).